FDA News

Home page 

Medical Forum 

Medical Exams 

Interactive Patient 

Medical mnemonics

Doctors Jobs 

Jobs For Nurses

Scholarships

Medical Courses

Medical Notes

Medical Textbooks 

Medical Multimedia

Medical Procedures 

Medical Cme 

Medical Slides 

Medical Software 

Medical products

Medical Humor 

Medical Magazines 

Medical News  

Medical links 

Medical Universities 

Medical Games

Site Map 

Doctors profiles 

Students profiles 

Medical Insurance

Medical Marketplace

Page Update Notice 

Feedback

Page copy protected against web site content infringement by Copyscape

 

 

 

  FDA Approves New Treatment for Gastrointestinal and Kidney Cancer  

 

Product name: Sutent (sunitinib)

Manufactured by: Pfizer

Mechanism of action:

is a tyrosine kinase inhibitor working through multiple targets to
deprive the tumor cells of the blood and nutrients needed to grow.

Indications:

Sutent was approved for the treatment of patients with gastrointestinal
stromal tumors (GIST) whose disease has progressed or who are unable to
tolerate treatment with Gleevec, the current treatment for GIST patients.
 

Side effects:

  • diarrhea,

  • skin discoloration

  • mouth irritation

  • weakness

  • altered taste

  • fatigue

  • high blood pressure

  • bleeding

  • swelling

  • taste disturbance

  • Hypothyroidism was also
    observed.
     

Source: FDA News

Date: January 26, 2006

Links:

 

 
Google
Web welovelmc.com

Privacy policy . Copyright . Disclaimer  Send Feedback   Join  Mailing Lists